This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by bluebird bio
Information provided by (Responsible Party):
bluebird bio Identifier:
First received: August 19, 2016
Last updated: April 7, 2017
Last verified: April 2017
This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 15 subjects ≥12 and ≤50 years of age with transfusion-dependent β-thalassemia (TDT), also known as β-thalassemia major, who do not have a β0 mutation at both alleles of the hemoglobin β (HBB) gene. The study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin BB305 Drug Product.

Condition Intervention Phase
Beta-Thalassemia Genetic: LentiGlobin BB305 Drug Product Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia, Who do Not Have β0/β0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector in Subjects ≥12 and ≤50 Years of Age

Resource links provided by NLM:

Further study details as provided by bluebird bio:

Primary Outcome Measures:
  • The proportion of treated subjects who meet the definition of "transfusion independence" (TI). TI is defined as Hb ≥9g/dL without any RBC transfusions for a continuous period of ≥12 months at any time during the study after drug product infusion. [ Time Frame: 12 - 24 months post-transplant ]

Secondary Outcome Measures:
  • Engraftment defined as an absolute neutrophil count ≥500 cells/µL for 3 consecutive days [ Time Frame: 24 months post-transplant ]
  • Detection of vector-derived replication competent lentivirus (RCL) using a RCL screening assay [ Time Frame: 24 months post-transplant ]
  • Frequency of events of insertional mutagenesis leading to clonal dominance or leukemia [ Time Frame: 24 months post-transplant ]
  • Frequency of clinical adverse events [ Time Frame: 24 months post-transplant ]
  • Percentage of subjects with a reduction in the mL/kg RBC transfused from Month 12 through Month 24 after drug product infusion of at least 50% compared to the average annual RBC transfusion requirement during the 2 years prior to enrollment. [ Time Frame: 24 months post-transplant ]

Estimated Enrollment: 15
Study Start Date: July 2016
Estimated Primary Completion Date: January 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LentiGlobin BB305 Drug Product
LentiGlobin BB305 Drug Product (autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human βA-T87Q-globin gene)
Genetic: LentiGlobin BB305 Drug Product
LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.


Ages Eligible for Study:   12 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects between 12 and 50 years of age, inclusive, at the time of consent or assent (as applicable), and able to provide written consent or assent.
  • Diagnosis of TDT with a history of at least 100 mL/kg/year of packed red blood cells (pRBCs) or ≥8 transfusions of pRBCs per year for the prior 2 years.
  • Clinically stable and eligible to undergo hematopoietic stem cell therapy (HSCT).
  • Treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history.

Exclusion Criteria:

  • Presence of a mutation characterized as β0 mutation at both alleles of the HBB gene.
  • Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV).
  • A white blood cell (WBC) count <3×10^9/L, and/or platelet count <100×10^9/L not related to hypersplenism.
  • Uncorrected bleeding disorder.
  • Any prior or current malignancy.
  • Prior HSCT.
  • Advanced liver disease.
  • A cardiac T2* <10 ms by magnetic resonance imaging (MRI).
  • Any other evidence of severe iron overload that, in the Investigator's opinion, warrants exclusion.
  • Participation in another clinical study with an investigational drug within 30 days of Screening.
  • Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician or investigator.
  • Prior receipt of gene therapy.
  • Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile subjects.
  • A known and available HLA-matched family donor.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02906202

Contact: bluebird bio

United States, California
Oakland, California, United States
United States, Illinois
Chicago, Illinois, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
Not yet recruiting
Marseille, France
Hannover, Germany
Not yet recruiting
Thessaloniki, Greece
Rome, Italy
Bangkok, Thailand
United Kingdom
London, United Kingdom
Sponsors and Collaborators
bluebird bio
Study Director: Mohammed Asmal bluebird bio
  More Information

Responsible Party: bluebird bio Identifier: NCT02906202     History of Changes
Other Study ID Numbers: HGB-207
Study First Received: August 19, 2016
Last Updated: April 7, 2017

Additional relevant MeSH terms:
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on September 21, 2017